Vipin Kohli, Ph.D
Vipin.kohli@hccs.edu
Contact Phone:
(713)781-6050
Education:
Ph.D
Skills:
Chemical synthesis of Oligonucleotides, Gene synthesis using Chemical and Enzymatic
methods, Modified Oligonucleotides, Antisense Oligonucleotides and Ribozymes as
potential therapeutics. RNAi (RNA Interference), Basic Molecular biology, DNA
transfection, Bacterial expression of cDNA constructs, General Biochemistry, drug
resistance during chemotherapy to Topoisomerase inhibitors, Multiple drug resistance,
Protein purification using HPLC, Northern, Southern & Western blotting. Molecular
cloning of Ca++ activated K+ channels and subsequent expression in Xenopous
Oocytes, RT-PCR, Quantitative PCR using Light Cycler, DNA sequencing using Applied
Biosystem Sequencer and related techniques. Worked as a Director of group in a
pioneering Biotechnology company in France from 1981-1985. Managed a core facility
for Oligonucleotides from 1989-1992 at Worcester Foundation for Experimental Biology
at Shrewsbury, Massachusetts, USA
CURRICULUM VITAE
Name:
Vipin Kohli, Ph.D.
Education:
B.Sc. (Science)
1968
Delhi University, Delhi, India
M.Sc. (Chemistry)
1970
A.M.U. University, Uttar Pradesh, India
Ph.D. (Biochemistry)
1977
All-India Institute of Medical Sciences,
New Delhi, India
Professional Experience:
2002-
Teaching: Adjunct Professor of Chemistry, teaching
undergraduates.
1997-2001
Research Associate: Baylor College of Medicine, Houston,
Texas: Molecular cloning of Ca++ activated K+ channels from red
cells and subsequent expression in HEK 293 and Xenopous
Oocytes. Quantitative RT-PCR using Light-Cycler (Roche). From
1997-2000: Member of Biohazard Committee at the V.A. Medical
Center at Houston, Texas.
1992-1995
Research Associate: M.D. Anderson Cancer Center, Houston,
Texas: Purification and analysis of p76 in HL-60 Cells, gene
expression of p76 (moesin) in mAMSA resistant HL-60 cells, and
study of possible inhibition of p-76 using Antisense
Oligonucleotides.
1989-1992
Manager: Worcester Foundation for Experimental Biology,
Shrewsbury, Massachusetts. DNA synthesis core, synthesis of
RNA as Ribozymes, modified Antisense Oligonucleotides and their
in-vivo toxicity for potential use as therapeutics
1985-1989
Project Investigator: M.D. Anderson Cancer Center at Houston,
Texas: Drug resistance during Chemotherapy, drug resistance to
Topoisomerase inhibitors, Protein purification, sequence analysis,
sub cellular fractionation, DNA sequencing, Tissue culture, assays
for apoptosis and basic cell biology methods including in-situ
hybridization.
1981-1984
Director (Chef de Groupe): Transgene S.A., Strasbourg,
France: A French genetic engineering company: Establish a team
involved in Oligonucleotides synthesis, solid phase synthesis and
automation of chemical and enzymatic synthesis of functional
Genes as well as Peptides.
1978-1981
Senior Research Associate (Wissenchaftlicher-Mitrabieter):
Institute of Organic Chemistry and Biochemistry, University of
Hamburg, Germany: Study and improve on methods of chemical
synthesis of DNA of biological interest. My supervisor was
Professor Dr. Hubert Koester.
1977-1978
Assistant Professor (Chargé de Recherché): INSERM U-95,
Nancy France: Synthesis of spin labeled Concanavalin-A and
other surface antigens.
1976-1977
Post-doctoral Research Assistant: University of London King’s
College, London, England: Preparation of building blocks for the
chemical synthesis of RNA. Supervisor: Dr. Colin B. Reese.
1970-1977
Graduate Student: All-India Institute of Medical Sciences, New
Delhi, India: Chemical synthesis of fragments of the structural
gene for adenocorticotropic hormone (ACTH). Efficient Chemical
Synthesis of DNA fragments using Phosphodiester and
Phosphotriester methodologies.
Bibliography
Paper Classifications:
#
^
@
DNA Chemistry
Biochemistry & Molecular Biology
Abstracts
#Kohli, V and Kumar, A (1978) Deoxypolynucleotides-Purification of
Deoxypolynucleotides by Solvent Extraction. Bulletin de Societe’ Chimie
Belgique 87: 21-25.
#Kohli, V and Kumar, A (1979) Deoxypolynucleotides-A Novel Protecting Group
for Deoxyguanosine. Indian Journal of Chemistry, Section B Organic Chemistry
Including Medicinal Chemistry 17: 272-273.
#Kohli, V and Kumar, A (1979) Deoxypolynucleotides-Synthesis of Thymidylyl(3’-5’)-thymidylyl-(3’-5’)-thymidine and a Comparison of Phosphodiester and
Phosphotriester Approach. Indian Journal of Chemistry, Section B Organic
Chemistry Including Medicinal Chemistry 17: 253-256.
#Kohli, V and Kumar, A (1979) Deoxypolynucleotides-Synthesis of
Deoxypolynucleotides Corresponding to Various Codons of Amino Acids by
Phosphotriester Approach. Indian Journal of Chemistry, Section B Organic
Chemistry Including Medicinal Chemistry 17: 257-260.
#Kohli, V and Kumar, A (1979) Deoxypolynucleotides-A Novel Protecting Group
for Deoxyguanosine. Indian Journal of Chemistry, Section B Organic Chemistry
Including Medicinal Chemistry 17: 272-273.
#Bloecker, H., Kohli, V and Koester, H (1979) Chemically Synthesized Gene for
Insertion into pBR322 Vector. Hoppe-Seylers Zeitung Fur Physiologische
Chemie 360: 1019-1020.
#Bloecker, H., Kohli, V and Koester, H (1979) Chemically Synthesized
Oligonucleotides as Useful Tools for Well Defined Cloning. Hoppe-Seylers
Zeitung Fur Physiologische Chemie 370: 325-326.
#Kohli, V., Bloecker, H and Koester, H (1980) Phosphorylation of Nucleosides
Using Molecular Sieves as Acid Scavengers. Tetrahedron Letters 21: 501-502.
#Kohli, V., Bloecker, H and Koester, H (1980) Triphenylmethyl (Trityl) group and
its Uses in Nucleotide Chemistry. Tetrahedron Letters 21: 2683-2686.
#Koester, H., Hoppe, N., Kohli, V., Kroeplin, M and Kulikowski, K (1981) Some
Improvements in the Synthesis of DNA of Biological Interest. Nucleic Acids
Research Symposium Series 7: 39-60.
#Koester, H., Kulikowski, K., Liese, T., Heikens, W and Kohli, V (1981) N-acyl
Protecting Groups for Deoxypolynucleotides-A Quantitative and Qualitative
Study. Tetrahedron 37: 363-370.
#Kohli, V., Balland, A and Lecocq, J.P (1982) Process for the Solid Phase
Synthesis of Deoxypolynucleotides. European Patent Issued to Transgene, S.A.
#Kohli, V., Balland, A., Saurwald, R., Staub, A., Wintzerith, M and Lecocq, J.P
(1982) Silica Gel: An Improved Support for the Synthesis of Oligonucleotides.
Nucleic Acids Research 10: 7439-7449.
^Lathe, R., Balland, A., Kohli, V and Lecocq, J.P (1982) Fusion of Restriction
Termini Using Synthetic Oligonucleotides. Gene 20: 187-195.
^Jaye, M., Salle, H., Schamber, F., Balland, A., Kohli, V., Findeli., Tolstochev, P
and Lecocq, J.P (1983) Isolation of a Human Antihemophilic Factor IX Clone
using a Unique 52 bases Synthetic Oligonucleotide Probe deduced from the
Amino Acid Sequence of Bovine Factor IX. Nucleic Acids Research 11: 23252334.
^Courtney, M., Buchwalder, A., Tessier, L-H., Jaye., Benavente, A., Balland, A.,
Kohli, V., Lathe, R., Tolstoshev and Lecocq, J.P (1984) High Level Expression of
Biologically Active Human alpha 1-antitrypsin in ecoli. Proceedings of the
National Academy of Sciences of USA 81: 669-673.
#Kohli, V and Jagdeeswaran, P (1985) Use of Reverse-Phase Columns for DNA
Sequencing by Maxam-Gilbert Method-A step towards automation, US Patent
Pending.
@Kunapali, S.P., Kohli, V and Kumar, A (1985) Role of Ceruloplasmin Gene in
Transformation. Presented at American Cancer Society Meeting held in October
1985 at Galveston, Texas.
@Kohli, V., Andersson, B., Steck, P., Freireich, E and Beran, M (1987) Changes
in Cellular Protein Patterns Concomitant to a Cytotoxic Drug mAMSA in Two
Human Myelogenous Leukemia Cell Lines HL-60 and KBM-3. Proceedings of the
American Association of Cancer Research 28: 288.
@Beran, M., Kohli, V and Nogueira-Costa, R (1998) Mechanisms of Resistance
to mAMSA in acute Myelogenous Leukemia. Experimental Hematology 16: 530.
^Beran, M and Kohli, V (1998) Current Concepts in Multidrug Resistance.
Highlights on Antineoplastic Drugs 4: 64-70.
@Beran, M., Nogueira-Costa, R., Skinner, L., Zwelling, L and Kohli, V (1988)
Alterations in the Topo II-mediated mAMSA Stimulated DNA-Protein Interactions
are Characteristics of High but not Low Level of Resistance to mAMSA and are
Concomitant with Deletion of a 76,000 Dalton Protein (p76). Second Conference
on DNA Topoisomerases in Cancer Chemotherapy held on October 17-19, 1988
at New York.
^Skinner, W., Murray, D., Kohli, V., Beran, M., McCredie, K.B., Freireich, E J and
Andersson, B (1990) Resistance to 4’-(9-acridinylamino) methanesulfon-manisidide (mAMSA) in Human Myeloid Leukemia. British Journal of Cancer 61:
51-55.
^Goodchild, J and Kohli, V (1991) Ribozymes that cleave an RNA sequence
from Human Immunodeficiency Virus: Effect of Flanking Sequences on Rate.
Archives of Biochemistry and Biophysics 284: 386-391.
@O’ Brien, S., Kantarjian, H., Pisa., Nowak, B., Kohli, V and Beran (1992)
Resistance to Hycamptamine (Hy:Topotecan) in Human Leukemia Cells (HL-60).
Fourth Conference on DNA Topoisomerases in Therapy held on October 26-29,
1992 at New York.
@O’ Brien, S., Kantarjian, H., Pisa, P., Nowak, B., Kohli, V and Beran, M (1992)
Resistance to Hycamptamine (Hy) in Human Leukemia Cells (HL-60). Blood 80:
207.
^Kohli, V and Temsamani, J (1993) Comparison of in-vitro Transcription Using
Various Types of DNA Templates. Analytical Biochemistry 208: 223-227.
^Koller, C.A and Kohli, V (1993) Purification of Genomic DNA using Heparin to
Remove Nuclear Proteins. Nucleic Acids Research 12: 2952.
^Beran, M., Pisa, P., O’ Brien, S., Andersson, B.S., Kurzrock, R., Siciliano, M.,
Cork, A., Kohli, V. and Kantarjian, H (1993) Biological Properties and Growth in
SCID Mice of a New Myelogenous Leukemia Cell Line (KBM-5) Derived from
Chronic Myelogenous Leukemia Cells in the Blastic Phase. Cancer Research 53:
3603-3610.
@Kohli, V and Koller, C.A (1995) Chimeric Antisense Oligonucleotides as
Inhibitors of Fusion Transcripts in Acute Leukemia. Blood 82: 528.
^Zhang, Bing-Mei., Kohli, V et.al (2001) Calmodulin binding to the C-terminus of
the small-conductance Ca++ activated K+ channel hSK1 is affected by
alternative splicing. Biochemistry 40: 3189-3195.
Manuscript in Preparation:
^Kohli, V et. al (2001) Alterations in Cellular Proteins Concomitant with
Acquisition of Resistance to 4’-(9-acridinylamino) methanesulfon-m-anisidide
(mAMSA) in Two Human Myelogenous Leukemia Cell Lines. Cancer Research
(In Preparation)
Invited Lectures
Gene Synthesis: at U 95, INSERM, Unité de Cancerologie et de Radiobiologie
at Nancy, France on October 30, 1976.
Synthesis of Deoxypolynucleotides at Laboratoire de Chimie Organique,
Université Scientifique et Medicale, C E R M O. , Grenoble, France on October
10, 1977.
Synthesis of Deoxypolynucleotides at Centro di Fisiologia Generale at Roma,
Italy on November 1, 1978.
Synthesis via Phosphotriester Approach at Laboratorio di Genetica ed
Evoluzionistica at Pavia, Italy on November 3, 1978.
Chemical Synthesis of Oligonucleotides by the Phosphotriester Method at
Genentech Inc., California, USA on February 9, 1981.
Synthesis of DNA of Biological Interest at Ciba-Geigy of Basel at Basel,
Switzerland on February 8, 1982.
Synthesis of DNA on Silica Gel Support by Phosphotriester Approach at
International Symposium on Synthetic Oligonucleotides in Molecular Biology held
on August 15, 1982 at University of Uppsala at Uppsala, Sweden.
SUMMARY OF RESEARCH EXPERIENCE
(Adapted from a grant proposal)
The principal investigator of this proposal has a long-standing interest in
synthetic biology, protein-nucleic acid interactions and, recently, protein-protein
interactions. He has done his graduate work on chemical synthesis of DNA of
biological interest from 1970-1977 (Ph.D in Biochemistry) at the All-India
Institute of Medical Sciences, New Delhi. From 1977-1982 he did post-doctoral
work with Professor Dr. Hubert Koester at the University of Hamburg at
Hamburg, Germany and with Professor Collin B. Reese at the University of
London King's College, London, mainly on the development of chemistries for
efficient synthesis of DNA and RNA of biological significance. He was then
appointed as Director of DNA and peptide synthesis group at Transgene
S.A, Strasbourg, France at development stages of a pioneer Recombinant DNA
venture. Duties involved collaborative efforts with Dr. Pierre Chambon and
associates at Strasbourg in molecular cloning and expression of human Factor
IX, Interferons, alpha 1-antitrypsin and hirudin.
In the United States he did work in identifying a lesion in a cell-line
rendered resistant to Amsacrine (mAMSA) a therapeutic drug which was
used in the frontline combination chemotherapy of Acute Myelogenous
leukemia (AML). A cellular protein with an apparent molecular weight of
76,000 Daltons (p76) was found to be missing in the in-vitro induced
resistant cells which has been purified and characterized.
From 1989-1992 he worked in the group of Professor Paul Zamecnik of
Harvard Medical School, MA and Principal Scientist in the development of
"third generation" of Antisense Oligonucleotides namely: Ribozymes and worked
as Manager of DNA and RNA synthesis core facility at Worcester Foundation for
Experimental Biology. Upon his return to Houston he is pursuing studies on the
Antisense Oligonucleotide based approach to transforming proteins particularly in
acute leukemias and understanding the role of p76 in resistance to mAMSA and
Topotecan. He is also involved in molecular cloning of Ca++ activated K+
channels which are believed to be involved in volume regulation.